Search 

TF Capital focuses on investment in the life sciences industry, primarily investing in early stage companies with high potential. Through strategic investments in various key areas and right partnerships, TF Capital hopes to capture opportunities in the rapidly expanding Chinese life sciences market. Our investment team has vast experience and resources in industry to assist our portfolio companies.

TheraIndx Life Sciences is a preclinical Contract Research Services Company based in Bangalore, India with Management team who have worked in Global Pharma in Drug Discovery and development progressing molecules from discovery to clinic. TheraIndx offers modular and integrated drug Discovery and development services to Pharma, Biotech and academic institutions across the globe. TheraIndx offers a wide range of animal disease models in infection, oncology, CNS and metabolic disorders along with Biomarker assays. Our Business models are Fee for services and also in partnerships till IND filing.

Theramix is developing imaging technology for diagnosis and imaging-based drug discovery and development. We have established a rapid drug testing platform for quickly assessing the efficacy and toxicity of drugs in animals. A cancer drug has been developed guided by in vivo imaging approaches. The new drug is designed to control tumor growth to make cancer manageable. Animal experiments show promising data on the cure of cancer with this drug.

Multi cancer early detection screening diagnostic solutions (liquid biopsy)

Pls check us at company website.

see company website

Tianda Pharmaceutical Limited (455.HK) is a Hong Kong listing company, concentrated in the R&D, manufacturing and distribution of biochemicals, biologics, biosimilars, CHC, dietary supplements and TCM.The company has two pharmaceutical factories, one TCM herbal slice plant, one GSP Company, one CSO company and a R&D center, and several operating
platforms separately located in Sydney, Hong Kong, Shenzhen, Zhuhai and Kunming.Shanghai Pharmaceutical Holding Co Limited, one of the top three largest pharmaceutical companies in China, has invested in Tianda Pharmaceuticals.
The mutual parties share their resources, therefore Tianda could explore and develop its business by utilizing the resources of Shanghai Pharmaceuticals.

Tianjin Chase Sun Pharmaceutical Co., Ltd. is a listed pharmaceutical company with market value of over RMB 10 billion.  It's a high-tech pharmaceutical health industry cluster that covers TCM granules, finished drugs, pharmaceutic adjuvants, active pharmaceutical ingredients, medical devices, medical and health management services and other areas.   Since 2015, the company has been ranked among the Top 100 Enterprises in China’s Pharmaceutical Industry.

For many years, Chase Sun has been focusing on researches and innovations in the five drug areas of critical, neoplastic, cardio-cerebrovascular, respiratory and neurodegenerative diseases, and dedicated to reducing China’s ICU fatality rate. It has already developed ace product catalog with independent IPRs represented by Xuebijing® injection and other first-aid medicines for critical diseases. A paper on RCT for Xuebijing’s Efficacy in Treatment of SCAP was published on the authoritative international critical medicine journal of Critical Care Medicine (CCM) in 2019 with corresponding authors of Prof. Bai Chunxue, Zhongshan Hospital, Fudan University and Shang Hongcai, Research Fellow of Dongzhimen Hospital, Beijing University of Chinese Medicine as well as first author of Prof. Song Yuanlin, Zhongshan Hospital, Fudan University. According to research, Xuebijing®reduced fatality rate of patients with severe pneumonia by 8.8%, made significant breakthrough in research methodology for evidence-based traditional Chinese medicine, reflected concrete clinical value of reduction of fatality rate of critical diseases, and created a new treatment pattern featured by combined use of Chinese and western medicine for patients with critical diseases.

Founded in 2007 with a management capital of 10 billion, fousing on healthcare and manufacturing investment. Portfolios includes ASYMCHEN, HOTGENBIO, SUNNOV and other more than 70 companies.